Century Therapeutics, Inc. Proceeds from Common Stock Issued
Century Therapeutics, Inc. (IPSC) reported Proceeds from Common Stock Issued of $549.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2026-08-12
- Century Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2026-06-30 was $347.00K.
- Century Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2026-03-31 was $202.00K, a 68.33% increase year-over-year.
- Century Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2025-12-31 was $53.00K.
- Century Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Century Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2025 was $173.00K, a 22.70% increase from fiscal 2024.
- Century Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2024 was $141.00K, a 72.67% decline from fiscal 2023.
- Century Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2023 was $516.00K, a 49.57% increase from fiscal 2022.
- Century Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2022 was $345.00K, a 61.97% increase from fiscal 2021.
| Period end | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 6 month as first filed | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $347.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $549.00K 10-Q · filed 2026-08-12 | $602.00K derived: sum of 3 quarters · filed 2026-08-12 | $602.00K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | $202.00K 10-Q · filed 2026-05-13 | $255.00K derived: sum of 2 quarters · filed 2026-05-13 | $255.00K derived: sum of 3 quarters · filed 2026-05-13 | $255.00K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | $53.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $53.00K derived: sum of 2 quarters · filed 2026-03-12 | $53.00K derived: sum of 3 quarters · filed 2026-08-12 | $173.00K 10-K · filed 2026-03-12 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2026-08-12 | $120.00K 10-Q · filed 2025-11-13 | -$482.00K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $120.00K 10-Q · filed 2026-08-12 | -$482.00K derived: sum of 3 quarters · filed 2026-08-12 | -$209.00K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | $120.00K 10-Q · filed 2026-05-13 | -$482.00K derived: sum of 2 quarters · filed 2026-05-13 | -$209.00K derived: sum of 3 quarters · filed 2026-05-13 | -$105.00K derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | -$602.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$329.00K derived: sum of 2 quarters · filed 2026-03-12 | -$225.00K derived: sum of 3 quarters · filed 2026-03-12 | $141.00K 10-K · filed 2026-03-12 | |
| 2024-09-30 | $273.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $377.00K derived: sum of 2 quarters · filed 2025-11-13 | $743.00K 10-Q · filed 2025-11-13 | $387.00K derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $104.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $470.00K 10-Q · filed 2025-08-14 | $114.00K derived: sum of 3 quarters · filed 2025-08-14 | $414.00K derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $366.00K 10-Q · filed 2025-05-15 | $10.00K derived: sum of 2 quarters · filed 2025-05-15 | $310.00K derived: sum of 3 quarters · filed 2025-05-15 | $434.00K derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | -$356.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | -$56.00K derived: sum of 2 quarters · filed 2025-03-19 | $68.00K derived: sum of 3 quarters · filed 2025-03-19 | $516.00K 10-K · filed 2025-03-19 | |
| 2023-09-30 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $424.00K derived: sum of 2 quarters · filed 2024-11-05 | $872.00K 10-Q · filed 2024-11-05 | $967.00K derived: sum of 4 quarters · filed 2024-11-05 | |
| 2023-06-30 | $124.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $572.00K 10-Q · filed 2024-08-08 | $667.00K derived: sum of 3 quarters · filed 2024-08-08 | $804.00K derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $448.00K 10-Q · filed 2024-05-09 | $543.00K derived: sum of 2 quarters · filed 2024-05-09 | $680.00K derived: sum of 3 quarters · filed 2024-05-09 | $728.00K derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $95.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $232.00K derived: sum of 2 quarters · filed 2024-03-14 | $280.00K derived: sum of 3 quarters · filed 2024-03-14 | $345.00K 10-K · filed 2024-03-14 | |
| 2022-09-30 | $137.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $185.00K derived: sum of 2 quarters · filed 2023-11-09 | $250.00K 10-Q · filed 2023-11-09 | $333.00K derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $48.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $113.00K 10-Q · filed 2023-08-09 | $112.00K 10-Q · filed 2022-08-11 | $196.00K derived: sum of 3 quarters · filed 2023-08-09 | $205.00K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $65.00K 10-Q · filed 2023-05-11 | $148.00K derived: sum of 2 quarters · filed 2023-05-11 | $157.00K derived: sum of 3 quarters · filed 2023-05-11 | $231.00K derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $83.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $92.00K derived: sum of 2 quarters · filed 2023-03-16 | $166.00K derived: sum of 3 quarters · filed 2023-03-16 | $213.00K 10-K · filed 2023-03-16 | |
| 2021-09-30 | $9.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $83.00K derived: sum of 2 quarters · filed 2022-11-10 | $130.00K 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $74.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $121.00K 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | $47.00K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |